Integrating Pediatric Pharmacogenomic Testing Into the Canadian Health Care System
NCT ID: NCT04249375
Last Updated: 2024-12-05
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
RECRUITING
150 participants
OBSERVATIONAL
2020-02-20
2025-10-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
We will conduct pilot testing of a pharmacogenomic testing panel and study how the tests and generated test results are utilized and understood by physicians, pharmacists, patients and their families.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
1. Implement a pilot pharmacogenomics program to test medication safety and effectiveness of antibiotics, analgesics and mental health medication to enhance prescribing decision-making.
2. Develop data collection forms to collect necessary patient information from the prescribing physicians.
3. Develop pharmacogenomics reports to return results to physicians, pharmacists, patients and their families.
4. Determine how the tests and results are perceived and utilized by physicians, pharmacists, patients and their families.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Keywords
Explore important study keywords that can help with search, categorization, and topic discovery.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
OTHER
OTHER
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Genome British Columbia
INDUSTRY
Genome Canada
OTHER
Dynacare Laboratories, Inc.
UNKNOWN
University of British Columbia
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Bruce Carleton
Director, Pharmaceutical Outcomes Programme
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Children's and Women's Health Centre of British Columbia
Vancouver, British Columbia, Canada
Children's Hospital of Eastern Ontario
Ottawa, Ontario, Canada
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Bruce Carleton, PharmD.
Role: primary
Related Links
Access external resources that provide additional context or updates about the study.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
H18-01383
Identifier Type: -
Identifier Source: org_study_id